GLAB:CA:CNSX-Gemina Laboratories Ltd (CAD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.7

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

500.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
DRUG:CA Bright Minds Biosciences Inc

+1.68 (+2.97%)

USD 0.38B
METX:CA METX

N/A

USD 0.10B
ACOG:CA Alpha Cognition Inc.

N/A

USD 0.05B
DTC:CA Defence Therapeutics Inc

+0.03 (+4.62%)

USD 0.03B
MDMA:CA Pharmala Biotech Holdings Inc.

N/A

USD 0.03B
DOSE:CA Rapid Dose Therapeutics Corp

-0.02 (-6.25%)

USD 0.03B
PHRM:CA PharmaTher Holdings Ltd

+0.01 (+2.33%)

USD 0.02B
TELI:CA Telescope Innovations Corp.

-0.03 (-7.32%)

USD 0.02B
BIOV:CA BioVaxys Technology Corp

-0.01 (-7.69%)

USD 0.01B
BETR:CA BetterLife Pharma Inc

-0.01 (-4.55%)

USD 0.01B

ETFs Containing GLAB:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.39% 8% B- 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.39% 8% B- 12% F
Trailing 12 Months  
Capital Gain 34.62% 62% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.62% 62% D 77% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.42% 63% D 58% F
Dividend Return -1.42% 63% D 58% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.07% 94% A 86% B+
Risk Adjusted Return -6.73% 56% F 57% F
Market Capitalization 0.05B 94% A 95% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.